title: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
abstract: Teriparatide [rhPTH(1-34)] increases bone mineral density and reduces the risk of vertebral fracture in women. We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg. All subjects also received supplemental calcium and vitamin D. The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies. Biochemical markers of bone formation increased early in the course of therapy and were followed by increases in indices of osteoclastic activity. Spine bone mineral density was greater than in placebo subjects after 3 months of teriparatide therapy, and by the end of therapy it was increased by 5.9% (20 microg) and 9.0% (40 microg) above baseline (p < 0.001 vs. placebo for both comparisons). Femoral neck bone mineral density increased 1.5% (20 microg; p = 0.029) and 2.9% (40 microg; p < 0.001), and whole body bone mineral content increased 0.6% (20 microg; p = 0.021) and 0.9% (40 microg;p = 0.005) above baseline in the teriparatide subjects. There was no change in radial bone mineral density in the teriparatide groups. Bone mineral density responses to teriparatide were similar regardless of gonadal status, age, baseline bone mineral density, body mass index, smoking, or alcohol intake. Subjects experienced expected changes in mineral metabolism. Adverse events were similar in the placebo and 20-microg groups, but more frequent in the 40-microg group. This study shows that teriparatide treatment results in an increase in bone mineral density and is a potentially useful therapy for osteoporosis in men.
authors.affiliation: Bone and Mineral Research Unit, Oregon Health and Sciences University and Veterans Affairs Medical Center, Portland, Oregon 97201, USA.
authors.forename: E S
authors.initials: ES
authors.lastname: Orwoll
authors.forename: W H
authors.initials: WH
authors.lastname: Scheele
authors.forename: S
authors.initials: S
authors.lastname: Paul
authors.forename: S
authors.initials: S
authors.lastname: Adami
authors.forename: U
authors.initials: U
authors.lastname: Syversen
authors.forename: A
authors.initials: A
authors.lastname: Diez-Perez
authors.forename: J M
authors.initials: JM
authors.lastname: Kaufman
authors.forename: A D
authors.initials: AD
authors.lastname: Clancy
authors.forename: G A
authors.initials: GA
authors.lastname: Gaich
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D001859:Bone Neoplasms / Q000139:chemically induced; D016723:Bone Remodeling / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism*; D012516:Osteosarcoma / Q000139:chemically induced; D051381:Rats; D011916:Rats, Inbred F344; D019379:Teriparatide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D019379:Teriparatide